aod9604 clinical trials efficacy fat loss side effects Does peptide demonstrate effective in humans? Stubborn fat that just won't

However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007

Additionally, AHK-Cu helps minimize muscle contractions, reducing the appearance of fine lines and wrinkles for smoother, more youthful-looking skin

AOD9604 and Heart Disease Though fat reduction and weight loss directly reduce the risk of heart disease, there is evidence to suggest that AOD9604 has beneficial effects on the heart beyond its ability to reduce fat burden

The frequency depends on individual needs, deficiency levels, and medical advice